Safety and efficacy of platelet-rich plasma injection for treatment of erectile dysfunction: a prospective randomized controlled study.

IF 2.4 3区医学 Q2 ANDROLOGY Basic and Clinical Andrology Pub Date : 2024-10-08 DOI:10.1186/s12610-024-00232-3

Ahmed M Ragheb, Amr M Lotfy, Mohamed Fahmy, Akrm A Elmarakbi

{"title":"Safety and efficacy of platelet-rich plasma injection for treatment of erectile dysfunction: a prospective randomized controlled study.","authors":"Ahmed M Ragheb, Amr M Lotfy, Mohamed Fahmy, Akrm A Elmarakbi","doi":"10.1186/s12610-024-00232-3","DOIUrl":null,"url":null,"abstract":"Background: Affected sexual relationships affect both the quality of life of men and women. Platelet-derived therapies are becoming increasingly popular in various medical and surgical fields because of their ability to aid in tissue healing and vascular remodeling. This study aimed to assess the safety and effectiveness of platelet-rich plasma (PRP) injections in treating patients with erectile dysfunction (ED).Results: Fifty-two participants with mild to moderate ED were divided into two groups: group A, who received three PRP penile injections, and group B, who received three saline injections (5 ml for each injection site). The International Index of Erectile Function (IIEF) was used to evaluate all participants. A month after the last injection, the PRP group's IIEF was 16.12 ± 1.25, while the placebo group's was 15.99 ± 1.21 (p = 0.683). Following a 3-month period, the IIEF for the PRP group was 16.44 ± 1.17, while the placebo group's was 16.31 ± 1.06 (p value = 0.653). Following a 6-month period, the IIEF for the PRP group was 16.35 ± 1.45, while that for the placebo group's was 16.23 ± 1.19 (p = 0.727). In terms of IIEF, there was no significant difference between the two groups after one, three, and six months of treatment.Conclusion: In brief, our research revealed no data to support the application of PRP injections in the management of mild-to-moderate ED.","PeriodicalId":8730,"journal":{"name":"Basic and Clinical Andrology","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460124/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic and Clinical Andrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12610-024-00232-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ANDROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Affected sexual relationships affect both the quality of life of men and women. Platelet-derived therapies are becoming increasingly popular in various medical and surgical fields because of their ability to aid in tissue healing and vascular remodeling. This study aimed to assess the safety and effectiveness of platelet-rich plasma (PRP) injections in treating patients with erectile dysfunction (ED).

Results: Fifty-two participants with mild to moderate ED were divided into two groups: group A, who received three PRP penile injections, and group B, who received three saline injections (5 ml for each injection site). The International Index of Erectile Function (IIEF) was used to evaluate all participants. A month after the last injection, the PRP group's IIEF was 16.12 ± 1.25, while the placebo group's was 15.99 ± 1.21 (p = 0.683). Following a 3-month period, the IIEF for the PRP group was 16.44 ± 1.17, while the placebo group's was 16.31 ± 1.06 (p value = 0.653). Following a 6-month period, the IIEF for the PRP group was 16.35 ± 1.45, while that for the placebo group's was 16.23 ± 1.19 (p = 0.727). In terms of IIEF, there was no significant difference between the two groups after one, three, and six months of treatment.

Conclusion: In brief, our research revealed no data to support the application of PRP injections in the management of mild-to-moderate ED.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

富血小板血浆注射治疗勃起功能障碍的安全性和有效性：一项前瞻性随机对照研究。

背景：受影响的性关系会影响男性和女性的生活质量。血小板衍生疗法能够帮助组织愈合和血管重塑，因此在各种医疗和外科领域越来越受欢迎。本研究旨在评估富血小板血浆（PRP）注射治疗勃起功能障碍（ED）患者的安全性和有效性：52名轻度至中度勃起功能障碍患者被分为两组：A组接受三次PRP阴茎注射，B组接受三次生理盐水注射（每个注射部位5毫升）。所有参与者都接受了国际勃起功能指数（IIEF）评估。最后一次注射一个月后，PRP 组的 IIEF 为 16.12 ± 1.25，而安慰剂组为 15.99 ± 1.21（P = 0.683）。3 个月后，PRP 组的 IIEF 为 16.44 ± 1.17，而安慰剂组为 16.31 ± 1.06（p 值 = 0.653）。6 个月后，PRP 组的 IIEF 为 16.35 ± 1.45，而安慰剂组为 16.23 ± 1.19（P = 0.727）。在 IIEF 方面，两组在治疗 1 个月、3 个月和 6 个月后没有明显差异：简而言之，我们的研究没有发现支持应用 PRP 注射治疗轻度至中度 ED 的数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Basic and Clinical Andrology Medicine-Urology

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

22 weeks

期刊介绍： Basic and Clinical Andrology is an open access journal in the domain of andrology covering all aspects of male reproductive and sexual health in both human and animal models. The journal aims to bring to light the various clinical advancements and research developments in andrology from the international community.